such-1 Antibody
Description
Potential Nomenclature Clarification
The query may involve a typographical error or misinterpretation of established antibody nomenclature. Key possibilities include:
-
Anti-SAE1 Antibody: Referenced in idiopathic inflammatory myopathies (IIM) and interstitial lung disease (ILD) research .
-
Anti-PD-1 Antibody: A well-characterized immune checkpoint inhibitor used in cancer therapy .
-
Anti-Her-2 Antibody: A monoclonal antibody targeting HER2/neu in breast cancer .
Case Study: Anti-SAE1 Antibody (Closest Phonetic Match)
Anti-SAE1 antibodies target the small ubiquitin-like modifier 1-activating enzyme subunit 1 (SAE1), associated with autoimmune disorders.
Clinical Features of SAE1-Positive Patients
Data from a 2024 Taiwanese cohort study (n=70 SAE1-positive patients) :
| Variable | Strong Positivity (>25 U) |
|---|---|
| Sex (female) | 60.0% |
| Mean age (years) | 57.70 ± 8.42 |
| Interstitial lung disease (ILD) | 60.0% |
| Idiopathic inflammatory myopathies (IIM) | 70.0% |
| Connective tissue disease (CTD) | 30.0% |
Key Findings:
-
Strong SAE1 positivity (>25 U) correlates with IIM diagnosis (70% vs. 5% for weak positives, p < 0.001) .
-
ILD developed in 60% of strong-positive patients, often post-IIM diagnosis .
Comparative Analysis of Antibody Classes
While "such-1" remains unidentified, foundational antibody mechanisms include:
Therapeutic Applications
| Antibody Type | Target | Clinical Use |
|---|---|---|
| Anti-PD-1 | PD-1 receptor | Enhances CAR T-cell tumor eradication |
| Anti-IgE | Immunoglobulin E | Asthma management |
| Anti-TNF-α | TNF-α | Rheumatoid arthritis, Crohn’s disease |
Antibody Validation Guidelines
Robust antibody characterization requires :
-
Positive Controls: Known antigen-expressing tissues.
-
Negative Controls: Knockout models or antigen absorption.
-
Dilution Optimization: Minimize nonspecific binding.
Research Databases for Antibody Verification
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
